OPKO Biologics

OPKO Biologics, formerly F.K.A. PROLOR Biotech, develops proprietary versions of therapeutic proteins and peptide drugs already approved for medical therapy, such as human growth hormone. The company's goal is to create longer-acting versions of existing therapies that could be administered, for example, by injection once a week rather than having to be administered daily.

The company's three primary products are designed to treat growth hormone deficiency, hemophilia, and type 2 diabetes.